000142208 001__ 142208
000142208 005__ 20240229111726.0
000142208 0247_ $$2doi$$a10.1016/j.ijcard.2018.08.002
000142208 0247_ $$2pmid$$apmid:30100224
000142208 0247_ $$2ISSN$$a0167-5273
000142208 0247_ $$2ISSN$$a1874-1754
000142208 0247_ $$2altmetric$$aaltmetric:47881437
000142208 037__ $$aDKFZ-2019-00022
000142208 041__ $$aeng
000142208 082__ $$a610
000142208 1001_ $$0P:(DE-He78)ebbb855092f574cef61b6f3ce7640d87$$aXuan, Yang$$b0$$eFirst author$$udkfz
000142208 245__ $$aPrediction of myocardial infarction, stroke and cardiovascular mortality with urinary biomarkers of oxidative stress: Results from a large cohort study.
000142208 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000142208 3367_ $$2DRIVER$$aarticle
000142208 3367_ $$2DataCite$$aOutput Types/Journal article
000142208 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550484585_680
000142208 3367_ $$2BibTeX$$aARTICLE
000142208 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142208 3367_ $$00$$2EndNote$$aJournal Article
000142208 520__ $$aOxidative stress contributes to endothelial dysfunction and is involved in the pathogenesis of cardiovascular diseases (CVD). However, large population-based cohort studies are sparse and biomarkers of oxidative stress have not been evaluated for CVD risk prediction so far.The associations of urinary oxidized guanine/guanosine (OxGua) levels (including 8-hydroxy-2'-deoxyguanosine (8-OHdGuo)) and 8-isoprostane levels with myocardial infarction, stroke and CVD mortality were examined in a population-based cohort of 9949 older adults from Germany with 14 years of follow-up in multivariable adjusted Cox proportional hazards models.Both OxGua and 8-isoprostane levels were associated with CVD mortality independently from other risk factors (hazard ratio (HR) [95% confidence interval] of top vs. bottom tertile: 1.32 [1.06; 1.64] and 1.58 [1.27; 1.98], respectively). Moreover, CVD mortality risk prediction was significantly improved when adding the two biomarkers to the European Society of Cardiology's Systematic Coronary Risk Evaluation (ESC SCORE) tool. The area under the curve (AUC) increased from 0.739 to 0.752 (p = 0.001). In addition, OxGua levels were associated with stroke incidence (HR for 1 standard deviation increase: 1.07 [1.01; 1.13]) and 8-isoprostane levels were associated with fatal stroke incidence (HR of top vs. bottom tertile: 1.77 [1.09; 2.89]). With respect to myocardial infarction, associations were observed for both biomarkers in obese subjects (BMI ≥ 30 kg/m2).These results from a large cohort study add evidence to the involvement of an imbalanced redox system to the etiology of CVD. In addition, 8-isoprostane and OxGua measurements were shown to be useful for an improved CVD mortality prediction.
000142208 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000142208 588__ $$aDataset connected to CrossRef, PubMed,
000142208 7001_ $$0P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aGào, Xīn$$b1$$udkfz
000142208 7001_ $$aHolleczek, Bernd$$b2
000142208 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$udkfz
000142208 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b4$$eLast author$$udkfz
000142208 773__ $$0PERI:(DE-600)1500478-8$$a10.1016/j.ijcard.2018.08.002$$gVol. 273, p. 223 - 229$$p223 - 229$$tInternational journal of cardiology$$v273$$x0167-5273$$y2018
000142208 909CO $$ooai:inrepo02.dkfz.de:142208$$pVDB
000142208 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ebbb855092f574cef61b6f3ce7640d87$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142208 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142208 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142208 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142208 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000142208 9141_ $$y2018
000142208 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142208 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142208 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142208 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CARDIOL : 2017
000142208 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142208 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142208 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142208 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142208 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142208 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142208 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142208 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142208 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142208 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142208 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000142208 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000142208 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000142208 980__ $$ajournal
000142208 980__ $$aVDB
000142208 980__ $$aI:(DE-He78)C070-20160331
000142208 980__ $$aI:(DE-He78)G110-20160331
000142208 980__ $$aUNRESTRICTED